ADHD-Europe Mini-Congress 9th April 2022 – Live From Cyprus

Prof Henrik Larsson (Örebro University SE) who is the es Coordinator of the TIMESPAN Research Project https://timespan.eu/ will be presenting **Management of cardiometabolic disease and treatment discontinuity in adults with ADHD: Project overview and preliminary results of the TimeSpan Research Project** at 14h55 CET Paris

Zoom link https://us02web.zoom.us/j/87333284201 No registration required

To view the full programme of our mini-congress visit
https://adhdeurope.eu/events-webinars/

Henrik Larsson is Professor of epidemiology .The overall objective of his research team's work on ADHD is to understand how genes and environments influence ADHD across the life span, to map developmental consequences of ADHD and to identify the benefits and risks associated with ADHD treatment interventions Henrik Larsson's team use large ADHD cohorts identified from national health registers, the Swedish twin register and clinical cohorts. These datasets contain valid diagnoses of ADHD, prospective measures of environmental risks, high throughput genotyping, longitudinal information on prescribed ADHD medications and assessments of serious medical (psychiatric and somatic problems) and functional (social, educational and occupational) outcomes. Henrik is a faculty member of IMPACT, ECNP, EUNETHYDIS, and the Behavioral Genetic Association.

What is the TimeSpan Project all about?

Advance clinical management of adults with ADHD and co-occurring cardiometabolic disease

Emerging evidence points at a significant association and shared genetic traits between adult attention-deficit/hyperactivity disorder (ADHD) and cardiometabolic conditions such as Obesity, Type-2 Diabetes, and cardiovascular disease, which, when inadequately treated, can lead to adverse outcomes and significant costs to society. Various national guidelines on cardiometabolic disease already highlight the importance of concurrent psychiatric disorders, but there is a lack of knowledge around ADHD. This is problematic given that ADHD is a common and serious complex chronic condition among adults.

TIMESPAN is a stellar consortium led by international recognised leaders working together on an interdisciplinary basis, consisting of clinicians, epidemiologists, biostatisticians, geneticists and artificial intelligence computer scientists. A multidisciplinary approach using multi-source data from 10 countries in 4 continents will allow TIMESPAN to advance the clinical research and deliver new tools for data management, analytics and data collection that fits market needs (e.g. health authorities, health care systems and providers, pharmaceutical companies). One of our clinically relevant goals is to create personalised treatment goals for people with ADHD and co-occurring cardiometabolic diseases.

Our vision is to improve the lives of people with ADHD and co-occurring cardiometabolic diseases by updating consensus statements, providing recommendations for treatment guidelines and disseminating results widely to patients, clinicians and other stakeholders.

TIMESPAN

ADHD is one of the most common neurodevelopmental disorders affecting between 3% and 5% of adults worldwide.

Why the TimeSpan Project matters - Lack of knowledge around ADHD

According to the World Health Organisation (WHO), Cardiometabolic diseases (CMDs) are the number-one cause of death in the world.

ADHD is one of the most common neurodevelopmental disorders not only of childhood, as is often assumed by the public, but also one that can last into adulthood, affecting between 3% and 5% of adults worldwide.
In recent years, there has been increasing concern that adults with ADHD are at greater risk for developing adverse cardiovascular events, but screening, diagnosis, and treatment guidelines for ADHD patients with co-occurring cardiometabolic disease do not exist, as knowledge around ADHD still is far from complete. However, it is known that comorbidities, including cardiometabolic diseases, are common in ADHD and are estimated as the main cost drivers.[1]

Therefore, TIMESPAN aims to improve not only the assessment of the risks involved for patients, but also to review and improve already existing treatments for patients with ADHD who also have cardiometabolic disease.

(1)
Hodgkins P *et al.* (2011). Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. *Prim Care Companion CNS Disord,* 13(2): PCC.10m01030
Libutzki B *et al.* (2019). Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. *European Psychiatr: the journal of the Association of European Psychiatrists,* 58: pp. 38-44
Du Rietz E *et al.* (2020). Trajectories of healthcare utilization and costs of psychiatric and somatic multimorbidity in adults with childhood ADHD: a prospective register-based study. *J Child Psychol Psychiatry*, 61(9): pp. 959-968

Clinical Studies

ART-CARMA: ADHD Remote Technology (ART) study of cardiometabolic risk factors

Using a new ADHD Remote Technology ('ART') system, developed at King's College London (Kuntsi, Dobson et al.), the ART-CARMA project aims to obtain real-world data from the daily life of 300 adults with ADHD on the extent to which ADHD medication treatment and physical activity, individually and jointly, may influence cardiometabolic risks. A second main aim of the project is to obtain detailed real-world data from the patients' daily life on adherence to pharmacological treatment and its predictors and correlates, over a remote monitoring period of 12 months that starts from pre-treatment initiation. The remote assessments consist of both active (smartphone active app) and passive (smartphone passive app and a wearable device) monitoring. The wearable device is the new EmbracePlus developed by the SME partner **EMPATICA** https://www.empatica.com/en-eu/ . The ART system is linked to the **RADAR mobile-health platform** https://radar-base.org/

TIMESPAN

ART-CARMA involves two data collection sites: 150 participants will be recruited in London by the King's College London (KCL) team and another 150 participants in Barcelona by the Vall d'Hebron Research Institute (VHIR) team. The KCL team is led by Professor Jonna Kuntsi (Principal Investigator) and Professor Richard Dobson (CoInvestigator). Other KCL team members include Hayley Denyer and Dr Amos Folarin, and collaborating Consultant Psychiatrists Dr Susie Whitwell (South London and Maudsley, SLaM, adult ADHD clinic) and Dr Ulrich MullerSedgwick (Barnet, Enfield and Haringey Mental Health NHS Trust adult ADHD clinic). The VHIR team is led by Professor J. Antoni Ramos-Quiroga and among his collaborators are Dr Marta Ribasés as Coordinator of the Psychiatric Genetics Unit, the Psychiatrists Dr Vanesa Richarte and Dr Christian Fadeuilhe, the Psychologist Dr Montserrat Corrales, the Cardiologist Dr Ignacio Ferreira, the Endocrinologist Dr Andreea Ciudin, the Psychologist/researcher Carolina Ramos and Raquel Ibarz as Project Manager.

Get this downloadable booklet explaining 'Advance clinical management of adults with ADHD and co-occurring cardiometabolic disease' and 'Contribution to a healthier future for adults with ADHD https://timespan.eu/wp-content/uploads/2022/02/20220218_TIMESPAN_Folder_Patients_EN_Web.pdf
Many thanks to the TimeSpan Project for sharing their news with us!

If you can afford to, please consider making a donation to ADHD Europe– every euro makes a difference! Donations will be used to raise awareness of the work that still needs to be done for ADHD in Europe and globally. Donations are via this paypal link https://lnkd.in/du4VySa2

More information about ADHD Europe, visit our www.adhdeurope.eu
To catch up on our previous live events, visit https://www.youtube.com/c/broadcastingadhdeurope
Not to be missed! Share this announcement to your friends, family, colleagues !

If you can afford to, please consider making a donation to ADHD Europe – every euro makes a difference! Donations will be used to raise awareness of the work that still needs to be done for ADHD in Europe and globally. Donations are via this https://www.paypal.com/donate/?hosted_button_id=5ATHYRQ3CDG52

More information about ADHD Europe, visit www.adhdeurope.eu
To catch up on our previous live events, visit our YouTube channel
https://www.youtube.com/c/broadcastingadhdeurope

Not to be missed! Share this announcement to your friends, family, colleagues!

Follow us on social media Twitter, Facebook or Linkedin! and share our news about our webinars.

TIMESPAN